Silexion Therapeutics Corp. Files 8-K for Material Definitive Agreement
Ticker: SLXNW · Form: 8-K · Filed: Mar 14, 2025 · CIK: 2022416
Sentiment: neutral
Topics: material-agreement, corporate-action
Related Tickers: SLXN
TL;DR
Silexion Therapeutics (SLXN) filed an 8-K for a material definitive agreement. Big news coming.
AI Summary
Silexion Therapeutics Corp. (formerly Biomotion Sciences) announced on March 14, 2025, that it entered into a material definitive agreement. The company, incorporated in the Cayman Islands and operating in the biological products sector, is headquartered in Ramat Gan, Israel. This filing is a current report under the Securities Exchange Act of 1934.
Why It Matters
This 8-K filing indicates a significant business development for Silexion Therapeutics Corp., potentially impacting its operations, partnerships, or financial structure.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new risks or opportunities, and the specifics of this agreement are not detailed in the provided filing excerpt.
Key Players & Entities
- Silexion Therapeutics Corp (company) — Registrant
- Biomotion Sciences (company) — Former company name
- March 14, 2025 (date) — Date of report
- March 13, 2025 (date) — Earliest event reported
- Cayman Islands (jurisdiction) — State of incorporation
- Ramat Gan, Israel (location) — Address of principal executive offices
- 001-42253 (identifier) — Commission File Number
FAQ
What is the nature of the material definitive agreement?
The provided excerpt of the 8-K filing does not specify the details of the material definitive agreement, only that one has been entered into.
When was Silexion Therapeutics Corp. formerly known as Biomotion Sciences?
The date of the name change from Biomotion Sciences to Silexion Therapeutics Corp. was May 6, 2024.
What is Silexion Therapeutics Corp.'s primary business sector?
Silexion Therapeutics Corp. is in the BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) sector, SIC code 2836.
Where are Silexion Therapeutics Corp.'s principal executive offices located?
The principal executive offices are located at 12 Abba Hillel Road, Ramat-Gan, Israel.
What is the Commission File Number for Silexion Therapeutics Corp.?
The Commission File Number for Silexion Therapeutics Corp. is 001-42253.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 14, 2025 regarding Silexion Therapeutics Corp (SLXNW).